Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...

Over the past few months, investigative journalist Charles Piller has published—eg, in The Daily Mail, The New York Times, ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

There’s so much to process after an Alzheimer’s diagnosis. Whether it’s you or a loved one who has this disease, you’re ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer's disease, a secondary analysis of trial data showed. In ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...